DEA telehealth prescribing cliff hits a year before Medicare's
Congress extended Medicare telehealth payment through 2027, but DEA's authority to prescribe controlled substances without a prior in-person exam still expires Dec. 31, 2026.
Most health systems booked the February 2026 telehealth extension as a win and moved on. That was a partial read. The DEA telehealth prescribing cliff sits on an entirely separate calendar from Medicare payment, and it arrives first: DEA's authority for clinicians to prescribe Schedule II-V controlled substances without a prior in-person exam expires Dec. 31, 2026, a full year before the Medicare flexibilities lapse.
End dates per Federal Register/DEA, CAA 2026 (P.L. 119-75) and the CY 2027 PFS proposed rule; months calculated from Oct. 2026.
| Value (months from Oct. 2026) | Months until expiration |
|---|---|
| DEA controlled substances | 3 months from Oct. 2026 |
| Medicare geographic/site | 15 months from Oct. 2026 |
| Audio-only and tele-mental health | 15 months from Oct. 2026 |
| Hospital Care at Home | 48 months from Oct. 2026 |
Two telehealth calendars, not one
The Consolidated Appropriations Act enacted in February 2026 (P.L. 119-75) extended Medicare telehealth coverage through Dec. 31, 2027 and pushed the Acute Hospital Care at Home waiver to Sept. 30, 2030. Coverage was never the constraint on controlled-substance prescribing. That authority comes from the Drug Enforcement Administration, and it currently rests on a fourth temporary rule published Dec. 30-31, 2025 that sunsets at the end of 2026.
The temporary rule preserves remote prescribing of Schedule II-V medications, including audio-only initiation of buprenorphine for opioid use disorder. Two narrower final rules, covering buprenorphine and Department of Veterans Affairs practitioners, took effect Dec. 31, 2025 and survive the temporary rule's expiration. They cover a fraction of the volume most systems are running.
DEA's Unified Agenda targets a Special Registration and Limited State Telemedicine Registration final rule for November 2026, according to the Alliance for Connected Care's late-August update. The contents are not public. A final rule landing in November leaves weeks, not quarters, to register practitioners, retrain schedulers and reconfigure workflows before the January 1 switch.
Payment authority and prescribing authority now expire on different calendars, and the earlier date is the one nobody budgeted for.
Which service lines carry the exposure
Exposure is not evenly distributed. Virtual behavioral health, addiction medicine, ADHD evaluation and management, palliative care and hospice concentrate nearly all of it. These are the lines where the prescription is the visit, and where patients were often recruited on the promise that no in-person appointment would ever be required.
The volume is structural rather than residual. Telehealth has held near 6% to 7% of ambulatory visits since 2023 by Epic Research's count, which means the prescribing relationships at risk were built in a stable, post-emergency operating model. DEA and HHS cited the same pattern when justifying the 2025 extension, noting that a meaningful share of controlled-substance prescriptions still originate through telemedicine with no prior in-person visit and that abrupt expirations produce immediate access drops.
The operational math is unforgiving. If the temporary rule lapses without a workable special registration pathway, systems must convert a year's worth of remote prescribing relationships into in-person encounters inside ambulatory schedules that are already full. The realistic alternatives are attrition, gaps in therapy or referral to whoever has open panels.
Three deliverables before Q4 budget lock
First, get a count. Leaders need the number of active patients currently receiving controlled substances through telemedicine only, segmented by schedule, service line and prescriber. Most systems cannot produce that figure today because remote prescribing was never tracked as a distinct cohort.
Second, model in-person conversion capacity. If the cohort is 4,000 patients and the affected clinics can absorb 300 additional in-person slots per month, the arithmetic decides the strategy long before policy does. The model should name which sites absorb volume, which prescribers travel, and what the marginal cost per converted visit looks like against current panel economics.
Third, open the vendor contracts. Virtual behavioral health and addiction medicine partners are operating on the same expiration date. Contract language should assign, explicitly, who absorbs the disruption if remote prescribing authority lapses: continuity-of-care obligations, in-person referral responsibility, data handoff, and whether performance guarantees flex when federal authority changes. Those clauses are cheaper to negotiate in October than in January.
Payment rules are adding their own reporting burden
CMS's CY 2027 physician fee schedule proposed rule, released July 14, 2026, staggers the Medicare dates further. Geographic, originating-site and practitioner expansions run through Dec. 31, 2027, while audio-only coverage and the delayed in-person requirement for tele-mental health extend to Jan. 1, 2028.
The same proposed rule introduces new "BB" and "BC" telehealth platform modifiers. That change makes the platform behind a virtual visit a reportable data element, which pulls vendor selection into claims accuracy and compliance rather than leaving it a procurement decision. Systems running multiple virtual care platforms across service lines should expect mapping work in the revenue cycle before the modifiers go live.
Taken together, the picture for 2027 service-line planning is a set of authorities expiring on different calendars. Budgeting a virtual behavioral health line on Medicare's 2027 horizon while its prescribing authority expires in 2026 is a planning error that will not show up until patients cannot get refills.
